Federated Hermes Inc. Acquires 57,680 Shares of Humana Inc. $HUM

Federated Hermes Inc. grew its stake in Humana Inc. (NYSE:HUM) by 69.3% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 140,956 shares of the insurance provider’s stock after buying an additional 57,680 shares during the quarter. Federated Hermes Inc. owned 0.12% of Humana worth $34,461,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Elevation Point Wealth Partners LLC acquired a new stake in Humana in the 2nd quarter valued at $32,000. Zions Bancorporation National Association UT bought a new stake in shares of Humana in the 1st quarter valued at about $37,000. AlphaCore Capital LLC bought a new stake in Humana in the second quarter valued at approximately $39,000. CVA Family Office LLC lifted its holdings in Humana by 63.4% during the 2nd quarter. CVA Family Office LLC now owns 219 shares of the insurance provider’s stock valued at $54,000 after purchasing an additional 85 shares during the last quarter. Finally, Ransom Advisory Ltd acquired a new stake in Humana during the first quarter worth approximately $66,000. 92.38% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on HUM. Truist Financial dropped their price objective on Humana from $300.00 to $285.00 and set a “hold” rating for the company in a report on Monday, November 10th. Royal Bank Of Canada upped their target price on Humana from $283.00 to $322.00 and gave the stock an “outperform” rating in a report on Thursday, August 21st. Guggenheim reaffirmed a “buy” rating on shares of Humana in a report on Friday, October 3rd. Barclays decreased their price objective on shares of Humana from $245.00 to $234.00 and set an “equal weight” rating for the company in a research report on Tuesday, November 25th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Humana in a report on Wednesday, October 8th. Nine equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $296.84.

Humana Stock Performance

Shares of HUM opened at $250.04 on Wednesday. The firm has a market capitalization of $30.07 billion, a P/E ratio of 23.43, a P/E/G ratio of 1.50 and a beta of 0.46. Humana Inc. has a 52 week low of $206.87 and a 52 week high of $315.35. The stock has a 50 day moving average price of $262.35 and a two-hundred day moving average price of $257.72. The company has a debt-to-equity ratio of 0.68, a quick ratio of 2.02 and a current ratio of 2.02.

Humana (NYSE:HUM) last announced its earnings results on Wednesday, November 5th. The insurance provider reported $3.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.95 by $0.29. The company had revenue of $32.65 billion for the quarter, compared to analysts’ expectations of $31.99 billion. Humana had a return on equity of 12.86% and a net margin of 1.02%.Humana’s quarterly revenue was up 11.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $4.16 earnings per share. Equities analysts forecast that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Friday, December 26th will be issued a $0.885 dividend. The ex-dividend date is Friday, December 26th. This represents a $3.54 annualized dividend and a dividend yield of 1.4%. Humana’s dividend payout ratio is currently 33.18%.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.